Royalty Pharma plc is a key player in the biopharmaceutical industry, specializing in the acquisition of biopharmaceutical royalties and funding innovation. With a focus on collaboration ...

Atria Investments Inc lowered its stake in Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 47.6% during the fourth quarter, ...

Royalty Pharma is planning the biggest IPO of the year as the market’s appetite for biotech stocks remains strong. The company said in a filing with the US financial regulator that it plans ...

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45th Annual Health Care Conference on ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where Royalty Pharma Plc (NASDAQ:RPRX) stands against the other ...

State of Michigan Retirement System boosted its stake in shares of Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 16.2% ...

For instance, one study of 458 pharmaceutical and biotechnology license agreements found a 7% average royalty. That is attractive as a simple option, but it also ignores the investments and risks ...

Royalty Pharma Plc (NASDAQ:RPRX) is a funder of innovation in the biopharmaceutical industry and a buyer of biopharmaceutical royalties. It collaborates with innovators from research hospitals ...

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

Ladenburg, Germany, 13 March 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company developing innovative Antibody Drug Conjugates (ADCs), and HealthCare Royalty (HCRx) today ...

Ladenburg, Germany, 12 March 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company developing innovative Antibody Drug Conjugates (ADCs), and HealthCare Royalty (HCRx) today ...